WASHINGTON (Dow Jones)--The U.S. Supreme Court on Monday rejected an appeal by Pfizer Inc.'s (PFE) Wyeth unit of a $58 million Nevada judgment in favor of three women who claimed they developed breast cancer due to their use of the company's hormone-therapy drugs.
Wyeth argued that it was entitled to a new trial because the verdict in favor of the women was tainted because the jury was influenced by passion and prejudice.
The Supreme Court, in a short written order, said it wouldn't consider Wyeth's case.
Hormone-therapy drugs are used to treat symptoms of menopause and prevent osteoporosis. The plaintiffs alleged Wyeth concealed a link between the drugs and an elevated risk of breast cancer.
A Nevada jury awarded the women $134 million in 2007, but the trial judge in the case said the size of the award was excessive and reduced it to $58 million in 2008.
The Nevada Supreme Court said any taint in the jury's monetary award was cured by the judge's reduction of the damages Wyeth owed.
Monday's action marked the third time in the last year that the U.S. Supreme Court has refused to consider a Wyeth appeal in a hormone-therapy case.
The case is Wyeth v. Scofield, 10-1177.
-By Brent Kendall, Dow Jones Newswires; 202-862-9222; brent.kendall@dowjones.com
Tuesday, June 21, 2011
Pay Up! - US High Court Rejects Wyeth Appeal In Hormone-Therapy Case - WSJ.com
via online.wsj.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment